ArticleCurrent medical science2025
Yinchenhao Decoction Combined with Praziquantel Ameliorates Inflammation and Hepatic Fibrosis in Schistosoma japonicum-Infected Mice.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to investigate the therapeutic effects and underlying mechanisms of the combination of Yinchenhao decoction (YCHD) and praziquantel (PZQ) in a Schistosoma japonicum (S. japonicum)-induced mouse model of schistosomiasis.
methodsSix-week-old male BALB/c mice were randomly divided into five groups: control group, infected group, infected-PZQ group (I-PZQ), infected-YCHD group (I-YCHD), and infected-PZQ + YCHD group (I-PZQ + YCHD). The mice were infected with S. japonicum cercariae in infected group, I-PZQ group, I-YCHD group, and I-PZQ + YCHD group (n = 6 per group) and maintained for 63 days. From day 43 to day 63 postinfection, the mice received PZQ (150 mg/kg, intragastric gavage), YCHD (10 mL/kg, intragastric gavage), or a combination of both. The control and infected groups received equal amounts of sterile double-distilled water for the same period. At the end of the experiment, the mice were anesthetized with pentobarbital sodium and sacrificed. Serum alanine transaminase (ALT) and aspartate transaminase (AST) levels were measured. Network pharmacology analysis was used to predict the targets of YCHD in the treatment of schistosomiasis. Histopathological analysis, Western blotting, immunofluorescence, quantitative polymerase chain reaction and flow cytometry were employed to evaluate liver pathology and molecular changes.
resultsCompared with the other groups, the I-PZQ + YCHD group presented significantly decreased serum ALT and AST levels (P < 0.001). The I-PZQ + YCHD group exhibited improved pathological changes in the liver, as evidenced by reduced area of single granuloma (P < 0.01), granuloma area (P < 0.01), and Ishak score of liver fibrosis (P < 0.01). Network pharmacology analysis suggested that YCHD may alleviate schistosomiasis-related liver injury through the modulation of the endoplasmic reticulum stress (ERS) pathway. Western blot analysis revealed that ERS-related markers, including glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 alpha (IRE1α), X-box binding protein 1 (XBP-1), and C/EBP homologous protein (CHOP), were significantly downregulated in the I-PZQ + YCHD group (P < 0.05). Furthermore, the I-PZQ + YCHD group presented reduced hepatocyte apoptosis (P < 0.05), diminished hepatic macrophage infiltration (P < 0.05) and downregulated expression of proinflammatory cytokines (TNF-α, IL-1β and IL-6) (P < 0.05).
conclusionYCHD combined with PZQ reduced schistosomiasis-associated hepatic granulomatous inflammation and fibrosis by inhibiting hepatic apoptosis and ERS.
Indexed as
Identifiers
40736935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.